Azizi, H.; Knapp, J.P.; Li, Y.; Berger, A.; Lafrance, M.-A.; Pedersen, J.; de la Vega, M.-A.; Racine, T.; Kang, C.-Y.; Mann, J.F.S.;
et al. Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV. Vaccines 2023, 11, 977.
https://doi.org/10.3390/vaccines11050977
AMA Style
Azizi H, Knapp JP, Li Y, Berger A, Lafrance M-A, Pedersen J, de la Vega M-A, Racine T, Kang C-Y, Mann JFS,
et al. Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV. Vaccines. 2023; 11(5):977.
https://doi.org/10.3390/vaccines11050977
Chicago/Turabian Style
Azizi, Hiva, Jason P. Knapp, Yue Li, Alice Berger, Marc-Alexandre Lafrance, Jannie Pedersen, Marc-Antoine de la Vega, Trina Racine, Chil-Yong Kang, Jamie F. S. Mann,
and et al. 2023. "Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV" Vaccines 11, no. 5: 977.
https://doi.org/10.3390/vaccines11050977
APA Style
Azizi, H., Knapp, J. P., Li, Y., Berger, A., Lafrance, M.-A., Pedersen, J., de la Vega, M.-A., Racine, T., Kang, C.-Y., Mann, J. F. S., Dikeakos, J. D., Kobinger, G., & Arts, E. J.
(2023). Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV. Vaccines, 11(5), 977.
https://doi.org/10.3390/vaccines11050977
